[go: up one dir, main page]

WO2005037231A3 - Methods of detecting and treating facioscapulohumeral muscular dystrophy - Google Patents

Methods of detecting and treating facioscapulohumeral muscular dystrophy Download PDF

Info

Publication number
WO2005037231A3
WO2005037231A3 PCT/US2004/034462 US2004034462W WO2005037231A3 WO 2005037231 A3 WO2005037231 A3 WO 2005037231A3 US 2004034462 W US2004034462 W US 2004034462W WO 2005037231 A3 WO2005037231 A3 WO 2005037231A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscular dystrophy
methods
detecting
facioscapulohumeral muscular
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/034462
Other languages
French (fr)
Other versions
WO2005037231A2 (en
Inventor
Rossella G Tupler
Michael Green
Davide Gabellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of WO2005037231A2 publication Critical patent/WO2005037231A2/en
Anticipated expiration legal-status Critical
Publication of WO2005037231A3 publication Critical patent/WO2005037231A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention includes methods and compositions useful for treating or preventing facioscapulohumeral muscular dystrophy (FSDH), and animal models useful for identifying compounds effective in treating or preventing FSDH.
PCT/US2004/034462 2003-10-14 2004-10-14 Methods of detecting and treating facioscapulohumeral muscular dystrophy Ceased WO2005037231A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/686,491 2003-10-14
US10/686,491 US20050054012A1 (en) 2002-10-11 2003-10-14 Methods of detecting and treating facioscapulohumeral muscular dystrophy

Publications (2)

Publication Number Publication Date
WO2005037231A2 WO2005037231A2 (en) 2005-04-28
WO2005037231A3 true WO2005037231A3 (en) 2007-09-07

Family

ID=34465503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034462 Ceased WO2005037231A2 (en) 2003-10-14 2004-10-14 Methods of detecting and treating facioscapulohumeral muscular dystrophy

Country Status (2)

Country Link
US (1) US20050054012A1 (en)
WO (1) WO2005037231A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2175037B1 (en) 2008-09-26 2017-10-11 Genomic Vision Method for analyzing D4Z4 tandem repeat arrays of nucleic acid and kit therefore
WO2012024535A2 (en) * 2010-08-18 2012-02-23 Fred Hutchinson Cancer Research Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
EP2736531A4 (en) * 2011-07-29 2015-08-26 Hutchinson Fred Cancer Res METHODS AND COMPOSITIONS FOR MODULATING NATURAL IMMUNE RESPONSE AND / OR MYOGENESIS IN MAMMALS
WO2013120038A2 (en) * 2012-02-10 2013-08-15 Regents Of The University Of Minnesota Morpholino targeting dux4 for treating fshd
WO2013155330A1 (en) * 2012-04-11 2013-10-17 University Of Massachusetts Compositions and methods for characterizing and treating muscular dystrophy
US20150301067A1 (en) * 2012-11-05 2015-10-22 University Of Washington Through Its Center For Commercialization Methods and assays for facioscapulohumeral muscular dystrophy
CN110730819A (en) 2016-10-26 2020-01-24 索尼克马斯特有限公司 Improved production of cells of muscle lineage and therapeutic uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLAIR ET AL.: "Identification, characterization, and association analysis of novel genes from the bipolar disorder susceptibility locus on chromosome 4q35", PSYCHIATRIC GENETICS, vol. 15, 2005, pages 199 - 204 *
LYLE ET AL.: "The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes", GENOMICS, vol. 28, 1995, pages 389 - 397 *
WINOKUR ET AL.: "The evolutionary distribution and structural organization of the homeobox-containing repeat D4Z4 indicates a functional role for the ancestral copy in the FSHD region", HUMAN MOLECULAR GENETICS, vol. 5, 1996, pages 1567 - 1575 *

Also Published As

Publication number Publication date
WO2005037231A2 (en) 2005-04-28
US20050054012A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2003008623A3 (en) Methylation analysis using nicking agents
EP1691842A4 (en) Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
IL210631A0 (en) Compositions and processes for analyte detection
EP1700120A4 (en) Marker for neuromyelitis optica
WO2004069184A3 (en) Methods for treating, preventing and detecting helicobacter infection
PT1560812E (en) AMINOCYCLOHEXYL ETER COMPOUNDS AND THEIR USES
WO2004016160A3 (en) Redox polymer nanoparticles
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
WO2002098355A3 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
IL173843A0 (en) Assay for coronaviruses, reagents for use therein and kits containing the same
WO2005037231A3 (en) Methods of detecting and treating facioscapulohumeral muscular dystrophy
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2003087051A3 (en) Methods for identifying allosteric sites
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
AU2003238232A1 (en) Compositions and methods for preventing, treating and diagnosing diabetes
WO2003030719A3 (en) Methods and kits for use in selecting approaches to treating cancer
WO2004020980A3 (en) Assays for the detection of biliverdin in birds and reptiles
WO2004019889A3 (en) Inhibitors of post-amadori advanced glycation end products
WO2004037848A3 (en) Process for determining target function and identifying drug leads
WO2005000234A3 (en) Novel coronavirus inhibitors
WO2004073738A3 (en) Composition to be administered to a living being and method for marking agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase